Clinical Trial

daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT

Name: daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT — clinical trial record (NCT07588945)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.

Trial Details

NCT Number	NCT07588945
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Transplant-Related Disorder
Enrollment	438 participants
Start Date	2026-06-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-15